|
Entelos, Inc. announced today that UCB Pharma S.A. has signed an agreement with Entelos to conduct in silico research in the field of rheumatoid arthritis using the Entelos® Rheumatoid Arthritis PhysioLab® platform
FOSTER CITY, CA, USA | January 21, 2008 | Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today that UCB Pharma S.A. (“UCB Pharma”) has signed an agreement with Entelos to conduct in silico research in the field of rheumatoid arthritis (“RA”) using the Entelos® Rheumatoid Arthritis PhysioLab® platform. Financial terms were not disclosed.
The Entelos Rheumatoid Arthritis PhysioLab platform is an innovative and predictive computer model that simulates arthritic patients and drug effects and it has already been used successfully with other pharmaceutical partners to select targets and compounds, find the best doses for patients, and support clinical trial design.
“We are pleased to add UCB Pharma to our list of new customers,” commented James Karis, president and CEO of Entelos. “We believe that our RA PhysioLab platform enables more rapid assessment, evaluation, and testing of complex therapies in this chronic, debilitating disease that is most difficult to treat. We look forward to a productive and rewarding relationship with UCB in the years to come.”
About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, “virtual patients”, and toxicology reference systems to develop safer and more effective drugs and support pharmaceutical R&D and commercialization. In addition to internal drug programs in rheumatoid arthritis and women's health, Entelos provides customized technology and research services to global pharmaceutical and health-care companies in cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and skin sensitization. The company is also developing a model in oncology and is collaborating with the FDA to build a model of drug-induced liver injury. Entelos offers cost-effective drug development capabilities through its strategic alliance with India-based Jubilant Biosys.
SOURCE: Entelos Inc. |
